KZR vs. JAGX, ELDN, ANVS, CELU, CALC, KRON, MURA, IMMX, MNOV, and SCYX
Should you be buying Kezar Life Sciences stock or one of its competitors? The main competitors of Kezar Life Sciences include Jaguar Health (JAGX), Eledon Pharmaceuticals (ELDN), Annovis Bio (ANVS), Celularity (CELU), CalciMedica (CALC), Kronos Bio (KRON), Mural Oncology (MURA), Immix Biopharma (IMMX), MediciNova (MNOV), and SCYNEXIS (SCYX). These companies are all part of the "pharmaceutical preparations" industry.
Jaguar Health (NASDAQ:JAGX) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, community ranking, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.
Jaguar Health received 1702 more outperform votes than Kezar Life Sciences when rated by MarketBeat users. Likewise, 89.16% of users gave Jaguar Health an outperform vote while only 57.83% of users gave Kezar Life Sciences an outperform vote.
Kezar Life Sciences has a consensus target price of $11.00, suggesting a potential upside of 1,209.52%. Given Jaguar Health's higher possible upside, analysts clearly believe Kezar Life Sciences is more favorable than Jaguar Health.
Kezar Life Sciences has a net margin of 0.00% compared to Kezar Life Sciences' net margin of -423.11%. Jaguar Health's return on equity of -43.08% beat Kezar Life Sciences' return on equity.
Jaguar Health has higher revenue and earnings than Kezar Life Sciences.
In the previous week, Jaguar Health had 1 more articles in the media than Kezar Life Sciences. MarketBeat recorded 2 mentions for Jaguar Health and 1 mentions for Kezar Life Sciences. Kezar Life Sciences' average media sentiment score of 0.49 beat Jaguar Health's score of 0.00 indicating that Jaguar Health is being referred to more favorably in the media.
Jaguar Health has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500.
12.0% of Jaguar Health shares are owned by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are owned by institutional investors. 0.0% of Jaguar Health shares are owned by insiders. Comparatively, 7.9% of Kezar Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Kezar Life Sciences beats Jaguar Health on 8 of the 15 factors compared between the two stocks.
Get Kezar Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KZR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kezar Life Sciences Competitors List
Related Companies and Tools
